A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315.

Published in: Cancer discovery (2024)

In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor-resistant breast cancers. See related article by Dietrich et al., p. 446 (8).

Keyphrases

cell cycle
cell proliferation
machine learning
drug induced